Klertis

Sunitinib cyclamate, the active ingredient in Klertis, is a tyrosine kinase inhibitor presented as an oral formulation for systemic use. It is employed in the treatment of certain advanced cancers, notably metastatic renal cell carcinoma and gastrointestinal stromal tumours, by targeting multiple receptor pathways.

GNH USA supplies Klertis as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Klertis (sunitinib cyclamate) is used in oncology to inhibit tumor growth driven by tyrosine‑kinase pathways.

- Metastatic renal cell carcinoma: slows disease progression and extends survival. - Advanced gastrointestinal stromal tumor: reduces tumor burden and delays progression. - Other solid tumours (off‑label): may be considered under specialist supervision when standard options are exhausted.

Klertis may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Hypertension: elevated blood pressure requiring monitoring. - Diarrhoea: loose stools that may lead to dehydration. - Nausea: feeling of sickness often managed with anti‑emetics. - Hand‑foot syndrome: redness or swelling of palms and soles. - Anorexia: loss of appetite and possible weight loss.

Serious or Rare Side Effects: - Neutropenia: dangerously low white‑blood‑cell count. - Thrombocytopenia: reduced platelet levels increasing bleeding risk. - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Hepatic failure: severe liver enzyme elevation. - Severe hypertension: hypertensive crisis requiring urgent care. - Pulmonary haemorrhage: bleeding in the lungs, potentially life‑threatening.

Before initiating Klertis, clinicians should evaluate baseline health status and monitor patients regularly. - Blood pressure monitoring: check at baseline and periodically during therapy. - Liver function tests: assess hepatic enzymes before and during treatment. - Cardiac assessment: perform echocardiogram if pre‑existing heart disease is present. - Complete blood count: monitor for neutropenia and thrombocytopenia. - Contraindication in severe hepatic impairment: avoid or adjust dose. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Klertis interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase sunitinib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may require dose adjustment due to additive blood‑pressure effects. - CYP2C9 substrates (e.g., phenytoin): monitor plasma levels. - Digoxin: potential increase in serum concentration. - St. John’s wort: may modestly lower sunitinib levels. - Proton‑pump inhibitors: assess for any impact on absorption, though clinically modest.